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Abstract 
Purpose 
To compare time to a composite endpoint of non-fatal acute myocardial infarction, non-fatal 
stroke or all-cause mortality in patients with type 2 diabetes mellitus (T2DM) who had their 
treatment intensified with a dipeptidylpeptidase-4 (DPP-4) inhibitor or insulin (INS) following 
dual therapy (metformin, MET plus sulfonylurea, SU) failure.   
Methods 
A retrospective cohort study was conducted on 5,238 patients newly treated with either a DPP-
4 inhibitor or INS following dual therapy failure (2007-2014).  Data was sourced from UK 
General Practices. The risk of the composite outcome was compared between 2 treatment 
groups: MET+SU+INS (n=1,584) and MET+SU+DPP-4 inhibitor (n=3,654), while adjusting 
for baseline covariates. Follow-up was for up to 5 years. Propensity score matching analysis 
and Cox proportional hazard models were employed. 
Results 
Overall, 123 and 171 composite outcome events occurred among patients who added INS vs. 
DPP-4 inhibitor, respectively (44.5 vs 14.6 events per 1000 person-years). Addition of INS 
was associated with a significantly higher hazard ratio (HR) vs. the addition of a DPP-4 
inhibitor (adjusted HR 2.6 (95%CI: 1.9–3.4; p<0.01), an effect that was more pronounced in 
obese (BMI 30-34.9kg/m2) patients (corresponding aHR 3.6, 95%CI: 2.3-5.6, p< 0.01). 
Conclusion  
In routine clinical practice, intensification of MET+SU therapy by adding INS is associated 
with increased risk of cardiovascular events and death compared with adding a DPP-4 inhibitor. 
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These findings are in line with suggestions from previous studies regarding the cardiovascular 
safety of insulin in T2DM, but should be interpreted with caution.  
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Introduction 
There is evidence that tight glucose control, especially in the early years after diagnosis, 
reduces the risk of long-term cardiovascular (CV) complications in patients with type 2 
diabetes mellitus (T2DM). 1, 2 International guidelines therefore recommend an 
individualized treatment strategy to achieve and maintain target levels of glycaemic control. 
3  Metformin (MET) is the usual first-line drug therapy when diet and exercise alone are 
insufficient. 3, 4 It used to be the case during the period of this retrospective analysis, that the 
recommended second-line therapy after MET was sulfonylurea (SU), 4 and because of the 
progressive decline in beta cell function many patients failed to maintain adequate levels of 
HbA1c despite up-titration to maximum tolerated doses of dual therapy (MET+SU).  
However, recent guidelines give more flexibility in prescribing choices.5 
 
Several treatment options are available when MET and SU dual therapy is insufficient, 3 but 
there is very limited data on cardiovascular (CV) and diabetes-related outcomes in this group 
of patients to inform decision-making about third-line treatments.  For many patients the 
choice includes adding basal insulin (INS) or a DPP-4 inhibitor as a third oral agent. There 
are concerns about the CV safety of INS in T2DM, 6-10 but these studies have mainly 
investigated the use of INS per se, as monotherapy or in combination with metformin. 6-10 
On the other hand, the UKPDS 11 and ORIGIN 12 trials have demonstrated the safety of INS, 
while recent prospective RCTs have shown the CV outcomes of DPP-4 inhibitors are non-
inferior to placebo. 13, 14 However, no RCT has compared INS with DPP-4 inhibitors either 
in terms of their CV safety or effectiveness as a third option after MET plus SU fails. 
Further work is needed to explore the CV safety of INS when used as a third line therapy, 
often in patients with longer duration disease and higher CV risk.  Insulin is known to exert 
antiatherogenic effects 15 and many patients prefer to delay INS treatment because of fear of 
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injections, weight gain and the risk of hypoglycaemia.  Therefore, adding a DPP-4 inhibitor 
to MET+SU is an effective alternative to lower HbA1c. Prior to recent RCTs which have 
demonstrated the safety of DPP-4 inhibitor, there has been some uncertainty about CV 
outcomes with DPP-4 inhibitors 13, 16 and till date, there are no comparative outcome studies 
available on DPP-4 inhibitor versus INS in patients with dual therapy failure. Therefore, the 
aim of the present study is to compare CV outcomes and mortality among patients with 
T2DM who, in routine clinical practice, intensified their treatment with the addition of INS or 
a DPP-4 inhibitor following dual therapy (MET+SU) failure.  
 
Methods 
Study design and data source 
We conducted retrospective cohort analyses of data from The Health Improvement Network 
(THIN) database, which contains anonymous patient data from more than 400 General 
Practices throughout England and Wales.  THIN has been used previously to evaluate 
diabetes-related outcomes in routine clinical practice. 17 
 
Study population 
The study population comprised a cohort of patients identified to have T2DM and registered 
to a practice for more than 12 months before the index date (January 1st 2007 - May 30th 
2014). The cohort included patients ≥ 18 years old who were newly treated with a DPP-4 
inhibitor or INS following MET+SU therapy failure. Patients who were administered other 
glucose-lowering therapies (GLTs) such as pioglitazone, glucagon-like peptide 1 receptor 
(GLP-1) agonists, sodium glucose co-transporter 2 (SGLT2) inhibitors, glinides and acarbose 
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were excluded from the study. Also excluded were patients with a baseline diagnosis of a CV 
condition.  Standardised computerized routines were used to identify and extract information 
on patients’ prescriptions for GLTs using British National Formulary (BNF) codes, and 
patients’ diagnosis of disease conditions using Read codes.  Read codes used in defining the 
outcome of events are summarized as electronic supplementary material (ESM).   
 
Exposure 
The exposures were incident intensification prescription of INS (long-acting, short or fast-
acting, or biphasic) or a DPP-4 inhibitor (sitagliptin, vildagliptin, saxagliptin, linagliptin) as 
3rd line GLT following dual (MET+SU) treatment failure. The follow-up period commenced 
from the index date (the date of incident intensification prescription) through to the date of a 
censoring outcome event until a switch to, or addition of, another anti-diabetic drug, up to 5 
years after the index date.  The study end date was May 30th 2014. Patients were segregated 
into two treatment groups based on the GLTs they received at baseline: MET + SU + INS vs. 
MET + SU + DPP-4 inhibitor (reference/control group).  
 
Outcome 
The primary composite outcome was time to diagnosis of predefined events. These included 
non-fatal acute myocardial infarction (AMI), non-fatal stroke and all-cause mortality. 
Secondary outcomes included CV events (non-fatal AMI, non-fatal stroke and CV-related 
deaths combined), all-cause deaths and CV-related deaths. Read codes used for identifying 
AMI and strokes are included in ESM Table 1.  CV-related deaths were included where the 
cause of death was documented.  Subjects whose cause of death could not be verified were 
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ignored in the CV deaths analysis. The risks of events in the study population were compared 
between the two treatment groups.  In addition, descriptive analysis of the glycaemic and 
body weight responses of patients in each treatment group was conducted. 
 
Covariates  
Covariates were selected a priori on the basis of clinical significance. These are baseline 
demographic and medical parameters, and they include: age, gender, social deprivation 
(measured using Townsend’s index scores), body weight, body mass index (BMI), HbA1c, 
total cholesterol levels, low-density lipoprotein (LDL), high-density lipoprotein (HDL), 
triglycerides, systolic and diastolic BP, smoking status, duration of diabetes, glomerular 
filtration rate (GFR), albumin levels and urinary albumin-creatinine ratio (ACR). Others 
included the use of lipid-lowering drugs, antihypertensive drugs, aspirin and the following 
comorbidities at baseline: coronary heart diseases (CHD) other than AMI, peripheral arterial 
disease (PAD), hypoglycaemia and heart failure.  
 
Statistical analyses 
Descriptive analysis of baseline characteristics was conducted for all patients and compared 
between the INS and DPP-4 inhibitor treated groups using t test for continuous variables and 
chi-squared test for categorical variables. Primary analysis estimated the time to the 
composite outcome of non-fatal AMI, non-fatal stroke or all-cause death in the entire cohort 
as well as propensity score-matched cohort. A propensity score (PS) model was estimated 
using a logistic regression model in which the treatment status was regressed on the baseline 
covariates. 18  We assessed the balance in baseline covariates between the treated (INS) and 
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reference (DPP-4 inhibitor) subjects using standardized differences before and after 
matching. 19  An absolute standardized difference > 10% indicated serious imbalance. The 
mean and frequency distribution of measured baseline covariates between treatment groups 
with the same estimated PS was examined and summarized.  Pairs of treated group and 
reference subjects were matched based on their estimated treatment probabilities using 
logistic regression. The average treatment effect on the treated (ATT) was estimated by 
finding at least 1 match for each of the treated subjects from the reference group. PS was 
considered as a prognostic covariate and included in a Cox proportional hazards regression 
model. 
Crude and adjusted Kaplan–Meier estimates of survival functions were obtained for the 
treatment groups in the full cohort and PS-matched cohort.  From these survival functions, we 
computed the absolute reduction in the probability of an event occurring within a 5-year 
follow-up. The marginal hazard ratios were also estimated to enable us to quantify the 
adjusted hazard of an event occurring in the INS treated group compared to the DPP-4 
inhibitor group. Proportional hazards assumptions were confirmed through Schoenfeld 
residuals test. 20  Point estimates with 95% confidence intervals (CI) at the conventional 
statistical significance level of 0.05 were used in the regression models. Missing data among 
covariates was accounted for with multiple imputations using the chained equation (MICE) 
model. 21  All analyses were conducted using Stata Software, version 13. 22 
 
Subgroup and Sensitivity Analyses 
We examined the hazard ratio of an event occurring in subgroups of patients with BMI 
between 30 to 34.9kg/m2 and those with BMI ≥ 35kg/m2. BMI categories were broken down 
into BMI <30, 30-34.9, and >35kg/m2 distinguishing overweight, obese and morbidly obese 
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because NICE refer to BMI >35 as arbitrary cut off for certain prescribing choices rather than 
patient numbers in each group. Sensitivity analysis was aimed at examining the assumption 
of no unmeasured binary confounding variable. 23, 24 Assumption was made for an 
unmeasured covariate that would increase the odds of assigned treatment. 18 Sensitivity 
analysis was applied to Kaplan-Meier survival functions in the PS-matched cohort.  In 
addition, a sensitivity analysis was carried out to compare results of covariates with missing 
data with those having multiple-imputed data to assess the reliability of the outcomes and the 
impact of missing data. 
 
Biases 
Our analysis employed the “new user” design to minimize biases associated with prevalent 
use of intensification regimens. 23  In an approach similar to that used in as-treated analyses, 
we used the intensification regimen to define drug exposure; post index date exposure to any 
GLT other than a DPP-4 inhibitor or INS was not permitted in our study to reduce 
confounding by indication.  
Immortal-time bias was also addressed by ensuring subjects diagnosed with outcome events 
on or before the index date were excluded.  In addition, to eliminate bias that may occur from 
Kaplan–Meier estimates of survival functions due to an unbalanced distribution of covariates, 
we used the stratified log-rank test to compare the equality of the survival curves in the 
matched sets (Kaplan-Meier survival curves were estimated separately for INS treated and 
compared with DPP-4 inhibitor treated participants in the PS-matched sample). 25  
 
Results 
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General patient characteristics  
After screening 8,654 patients who intensified MET+SU treatment with a 3rd line drug, 5,238 
patients made the criteria for cohort entry and were assigned to one of two treatment groups 
as outlined in Figure 1. The number (proportion) of patients assigned to each treatment group 
included: n=1,584 (30%) for MET + SU + INS and n=3,654 (70%) for MET + SU + DPP-4 
inhibitor.  
Patients had a mean age of 56 yrs and constituted of 56% male. Compared with patients who 
added a DPP-4 inhibitor, those who added INS to MET+SU before PS matching had higher 
mean HbA1c levels of 9.9% (85mmol/mol) vs 9.2% (77mmol/mol), respectively and many of 
the measured covariates had a standardized difference above the 0.10 level (Table 1). The 
application of PS matching resulted in the inclusion of 3,168 patients (1,584 MET+SU+INS 
matched 1:1 with MET+SU+DPP-4 inhibitor) and brought into balance the distributions of 
the measured covariates. Apart from previous hypoglycaemia and a diagnosis of other CHD, 
the baseline characteristics of the matched sample were not statistically different; as a result, 
the systematic differences between INS and DPP-4 inhibitor subjects in the original sample 
have been substantially reduced or eliminated in the matched sample (Table 1). This shows 
that the differences between the treatment groups have been reduced by PS matching and 
adequate balance on baseline covariates has been induced by the specification of the PS 
model used. 
 
Time to composite outcome 
The time to a composite outcome in the cohort of patients is summarised in Table 2. The 
median time before the composite outcome among the DPP-4 inhibitor users was longer at 
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2.4 years (IQR: 1.1-3.8) compared to INS users (2.1 years, IQR: 0.9-3.6). The survival 
analysis showed the 5-year cumulative incidence of composite outcome was 9% with DPP-4 
inhibitor and 23% with INS. 
Estimating survival curves and survival effects 
Crude Kaplan–Meier (KM) survival curves for INS subjects and the reference DPP-4 
inhibitor subjects in the full original sample are reported in Figure 2a. The result showed 
there was a significant difference between the two curves; log-rank test p<0.001. The KM 
survival curves obtained from the PS matched sample are summarized (stratified log-rank test 
p< 0.001) (Figure 2b). From the estimated survival curves, our data showed that patients who 
intensified treatment with INS were significantly more likely to experience a composite 
outcome than those who added a DPP-4 inhibitor.  For example, from the matched sample, 
the probability of dying or experiencing a CV event at 3 yrs was 0.11 (95% CI, 0.10-1.03) 
with INS and 0.03 (95% CI, 0.02-0.04) with a DPP-4 inhibitor. 
Overall, there were 123 and 171 composite outcome events among patients who added INS 
vs. a DPP-4 inhibitor, respectively (44.5 vs 14.6 events per 1000 person-yrs).  The rate of 
occurrence remained the same after matching. The adjusted hazard ratio (aHR) from the PS-
matched model was 2.6 (95% CI: 1.9–3.4; p< 0.01) (Table 2).  A breakdown of the number 
of component outcome events showed the following: the number of CV events (non-fatal 
AMI, non-fatal stroke or CV-related deaths) was 95 and 94 among patients who added INS 
vs. a DPP-4 inhibitor, respectively (18 vs 8 events per 1000 person-yrs; p<0.01); all-cause 
deaths were 124 vs 64 events, respectively (23 vs 5 events per 1000 person-yrs) (Table 2). 
 
Subgroup and other analyses 
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Our data showed that in the normal BMI group (BMI <30kg/m2), the composite outcomes 
were 147 and 90 among patients who added INS vs a DPP-4 inhibitor, respectively (49 vs 20 
events per 1000 person-yrs; aHR 2.32 (1.75-3.10); p< 0.001). In a subgroup of patients with 
BMI 30-34.9kg/m2, the composite outcomes were 54 and 44 among patients who added INS 
vs a DPP-4 inhibitor, respectively (46 vs 12 events per 1000 person-yrs; aHR 3.6 (2.3-5.6); 
p< 0.01).  The subgroup with BMI ≥ 35kg/m2 had 30 and 37 composite events from 
intensification with INS vs a DPP-4 inhibitor (30 vs 11 events per 1000 person-yrs; aHR 2.4 
(1.4-4.0); p< 0.01) (Table 2).   
 
Stratification analysis across baseline BMI categories showed the risk of composite outcome 
among obese (BMI 30-34.9kg/m2) patients was not significantly different to those of normal 
BMI category (BMI <30kg/m2) patients. The risk of composite outcome between the 
morbidly obese group (BMI ≥35kg/m2) was also not significantly different to that of obese 
BMI (BMI 30-34.9kg/m2) cohort (HR 0.77, 95%CI; 0.56-1.05, P=0.1). However, the 
morbidly obese BMI group was associated with a reduced risk of composite outcome 
compared to the normal BMI category (HR 0.61; 95% CI, 0.45-0.81, p=0.001). 
In terms of glycaemic response, INS vs DPP-4 inhibitor users showed absolute mean 
reduction in HbA1c of -1.3% (14mmol/mol) vs -1.0% (11mmom/mol), respectively (P < 
0.001). With the exception of the period between 48 weeks and 1 year, the mean reduction in 
HbA1c was not significantly different between INS and DPP-4 inhibitor over time. (ESM 
Figure 1) The glycaemic response was also examined across the three subgroups of BMI 
categories. Among patients who intensified their treatment with INS, the greatest glycaemic 
response was observed in the subgroup with normal BMI category (-1.5%, p<0.001) while 
the subgroup of obese and morbidly obese patients exhibited lesser but similar level of 
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glycaemic response (-0.9% and -0.9%, respectively). The greatest glycaemic response 
observed among patients who added a DPP-4 inhibitor was observed in the subgroup with 
normal BMI level (-1.8%). This was followed by obese and morbidly obese subgroup (-1.1% 
and -0.8%, respectively). (ESM Figure 2)  
An absolute significant body weight increase was observed with INS (1.2kg, P < 0.001), 
whereas DPP-4 inhibitor showed a non-significant weight loss (-0.1kg, P = 0.5). From our 
data, INS users appeared to have consistently gained weight after the first year of treatment 
intensification. (ESM Figure 3) An assessment of the body weight changes across the BMI 
categories show that in both INS vs DPP-4 inhibitor treatment groups only the morbidly 
obese BMI subgroup experienced a reduction in body weight (-2kg vs -2.3kg, respectively, 
ESM Figure 4).  
Further analysis on gender related outcomes showed that within the female population, the 
number of composite outcomes were 105 and 67 among patients who added INS vs a DPP-4 
inhibitor, respectively (39 vs 14 events per 1000 person-yrs; aHR 2.34 (1.68-3.28); p< 0.001). 
Whereas within the male population, the number of composite outcomes were 126 and 104 in 
patients who added INS vs a DPP-4 inhibitor, respectively (50 vs 15 events per 1000 person-
yrs; aHR 3.08 (2.32-4.09); p< 0.001). (Table 2) Nevertheless, comparative analysis results 
show the risk of composite outcome in female population was not significantly different to 
the risk in males (HR 0.84, 95%CI; 0.69-1.03, P=0.1).   
 
 
Sensitivity analyses  
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One of the analyses was to assess how strongly an unmeasured confounder would have to be 
associated with treatment selection in order for a previously statistically significant treatment 
effect to become statistically non-significant if the unmeasured confounder had been 
accounted for. However, a large majority of estimated effects of covariates in our study were 
not statistically significant. Therefore, we did not employ this sensitivity analysis. Moreover, 
the p value for the stratified log-rank test in the matched cohort was p<0.001.  Hence, the 
small p-value obtained in the primary analysis cannot be taken as an indication that the study 
is insensitive to unmeasured confounders.  The sensitivity analysis on missing data yielded 
comparable results to complete case models (aHR 2.3 (1.7-3.0); p< 0.001), which reflects 
results that are unlikely to be attributable to bias from missing information. The probability 
density functions of the PS matching of the treatment groups show there was no violation of 
the overlap assumption. 26 (ESM Figure 6) 
 
Discussion 
This study has shown that in people who may need to have more therapy to lower their 
glycaemia, those who are selected by their GP to have DPP-4 inhibitor were less likely to 
experience the composite outcome of non-fatal AMI, non-fatal stroke or death. Furthermore, 
the increased risk with INS was even higher among the subgroup of patients who were obese 
(BMI>30).  In the absence of a consensus on which third-line treatment is most appropriate 
when maximum tolerated doses of MET+SU fail to maintain adequate glycaemic control, this 
study identifies important differences in CV and mortality outcomes between two treatment 
options that are frequently used in patients with dual therapy failure.  
The risk-benefit balance and overall safety of a more intensive treatment strategy in T2DM 
has recently been questioned, 27 and in particular the use of INS has been associated with an 
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increase in life-threatening hypoglycaemia risk and mortality. 6  Other observational studies 
have also raised concerns about INS use in T2DM.  For example, a dose-response 
relationship between INS exposure and all-cause deaths was reported in a large Canadian 
population, 7 and worse survival was reported among INS treated patients (relative to 
those on MET+SU) in a study exploring the relationship between HbA1c and CV disease. 
8  More recently, adverse CV events and increases in all-cause mortality were reported in a 
cohort of patients who received INS compared with other agents, 9 and among those whose 
treatment was intensified to INS (compared with adding a SU) following failure of 
metformin monotherapy. 10 However, an important limitation of these observational studies 
was their inability to control for differences in HbA1c, 7 hidden confounders or allocation 
bias 8-10 because they compared INS therapy with either MET or SU, both of which are often 
used much earlier in the course of the disease.  The present study overcomes many of these 
limitations and specifically compared outcomes in a cohort of dual therapy failure patients 
without prior evidence of CV disease.  
 
The observation of an even higher hazard ratio for the composite of non-fatal AMI, non-fatal 
stroke and all-cause death among the obese subgroup is clinically important.  Insulin therapy 
is associated with weight gain, thereby increasing the amount of insulin required to control 
hyperglycaemia, 28, 29 at the expense of further weight gain, increased insulin resistance and 
potentially increased risk of CHD. 30 Our study population still had suboptimal glucose 
control (HbA1c > 8% or 64mmol/mol) despite treatment intensification with insulin. Our data 
shows patients in our study population have poor response to diabetes management, although 
this may not apply to most other populations. Therefore, patient factors associated with 
persistently high HbA1c might be an important determinant of increased mortality risks and 
may need to be further investigated. We would speculate that patients in our study may have 
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required high dose insulin treatment in order to achieve glycaemic targets. We have 
previously shown that the effectiveness of insulin therapy to lower HbA1c levels among 
overweight patients with diabetes is reduced. 31  
 
Research evidence has shown that increasing obesity typically confers an increased risk of 
CV diseases and CHD and there is the general idea that more marked obesity may be 
associated with a worse prognosis. A systematic review of over 250,000 patients in 40 
cohort studies followed patients for up to 3.8 years and reported that overweight and obese 
CHD patients have a lower risk for total and CV mortality compared with underweight and 
normal-weight CHD patients and in morbidly obese patients with a BMI ≥35 kg/m2, there 
was an excess risk for CV mortality without any increase in total mortality.32 However, data 
from our study contrasts this evidence as the morbidly obese group is observed to be 
associated with a reduced risk of composite outcome compared to normal BMI. Another 
study by Galal et al assessed 4.4-year mortality in 2,392 patients with PAD who had a high 
mortality risk, showed progressive reductions in mortality in obese groups, overweight and 
normal BMI groups compared to underweight patients.33 Although their results showed BMI 
was an independent predictor of greater mortality in the entire cohort, there was still a 
relationship between higher BMI and lower mortality in the overweight and obese PAD 
group. Lavie et al documented the inverse relationship between BMI and all-cause mortality 
in over 30,000 patients with preserved left ventricular systolic function. This study found the 
highest mortality in underweight patients, yet overweight, obese, and morbidly obese 
patients (BMI ≥35 kg/m2) had significantly lower mortality than those with ideal BMI (18.5 
to 25 kg/m2).34 A limitation to our data meant we could not examine the risk of CV 
outcomes or mortality outcomes within subgroups with specific CV co-morbidities. 
Therefore, we speculate that although obesity may be a powerful risk factor for all-cause 
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mortality events, patients with different cardiovascular co-morbidities may paradoxically 
have varying prognosis depending on the level of systemic vascular resistance and plasma 
renin activity. We therefore recommend that further studies to examine the factors that may 
influence the variation in CV and mortality risks across BMI categories. 
 
Our analyses were subject to a number of limitations that are inherent to observational 
studies. Firstly, we cannot be certain that the patients were fully compliant with their 
medication. Other factors apart from HbA1c may also influence the decision to intensify 
treatment in everyday practice. These may include tolerability, cost and patient’s preference. 
In addition, covariates were mainly included as baseline parameters and their effects were not 
assessed during the follow-up period, some of these variables are relevant during the entire 
observation period for monitoring outcomes. For example, the use of other medications such 
as antihypertensive drugs are shown to have significant benefits on CV and renal outcomes in 
people with diabetes, independently of their blood pressure lowering efficacy.35 In addition, 
evidence from recently published real-world data showed that sitagliptin-persistent treatment 
for a medium–long period is associated with an improved metabolic control, as well as to a 
reduction on CV risk.36 Unfortunately, the relationship between the different types of 
antihypertensive drugs or adherence to statin use cannot be explained from our data. 
Although we could not account for potential residual confounders such as compliance, 
indications for intensification treatments, markers of β-cell deterioration and differences in 
dosages, we were able to account for differences in the observed covariates and used robust 
analytical techniques to control confounding that may bias the results of the estimated 
treatment effects. Our use of propensity score matching to estimate average treatment effect 
in the dataset contributed to the balancing of treatment and comparison groups on the 
available covariates. However, this technique only accounts for observed covariates. 
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Although we ensured a thoughtful and thorough specification of the selection model was 
employed to successfully apply the propensity score matching technique and minimise bias, 
our study findings must be interpreted with caution in light of the above limitations. 
Furthermore, there are other newer agents which will most likely be used in place of insulin 
after MET+SU combination therapy such as GLP-1 agonist and SGLT-2 inhibitors given 
their benefit in weight and hypoglycaemia risk. The changing landscape of diabetes 
management could undermine the relevance of the clinical implications of findings from this 
study. 
Conclusion 
Patients with T2DM fail to maintain adequate levels of HbA1c despite up-titration to 
maximum tolerated doses of dual therapy (MET+SU).  Comparative effectiveness studies and 
RCTs which examine the risks of cardiovascular events or deaths from the co-administration 
of INS or DPP-4 inhibitor as 3rd line regimens are not reported. Conducting RCTs at this 
level of treatment is not without its numerous challenges.  We observed that among patients 
with diabetes who are receiving MET and SU therapy, the addition of insulin compared with 
DPP-4 inhibitor was associated with an increased risk of a composite of non-fatal 
cardiovascular outcomes and all-cause mortality.  The observed excess risk of adverse 
cardiovascular events was increased in patients who are obese. Insulin is a still a very 
important treatment option in the management of T2DM and our data is not clinically 
applicable until RCTs comparing insulin with DPP-4 inhibitors have been conducted. These 
findings require further investigation to clarify the risk associated with insulin, especially 
among obese patients with T2DM, in view of the increasing availability of other therapies. 
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Table 1: Characteristics of Patients at Treatment Intensification 
 Cohort 
 Full  Propensity Matched 
Baseline variable 
MET + SU + 
INS (n = 
1584) 
MET + SU + 
DPP-4 (n = 
3654) Std. diff a 
 MET + SU + 
INS (n = 
1584) 
MET + SU + 
DPP-4 (n = 
1584) Std. diff b 
Demographics        
Age (yrs), Mean (SD) 53.7 (14.8) 56.6 (11.5) -0.18  53.7 (14.8) 54.4 (12.8) -0.05 
Gender, No. (%)        
Male 770 (49) 2163 (59) -0.16  770 (49) 768 (48) 0.00 
Female 814 (51) 1491 (41) 0.16  814 (51) 816 (52) 0.00 
Townsend deprivation, No. (%)        
Least deprived 294 (19) 802 (22) -0.07  294 (19) 302 (19) -0.01 
Less 300 (19) 733 (20) -0.03  300 (19) 336 (21) -0.06 
Average 333 (21) 782 (21) 0.00  333 (21) 295 (19) 0.06 
More 352 (22) 711 (19) 0.05  352 (22) 349 (22) 0.01 
Most deprived 305 (19) 626 (17) 0.04  305 (19) 302 (19) 0.01 
Clinical Parameters, Mean (SD)        
HbA1c (%) 9.9 (2.9) 9.2 (2.7) 0.18  9.9 (2.9) 9.8 (3.7) 0.03 
BMI (kg/m2) 29.8 (6.7) 32.3 (6.3) -0.30  29.8 (6.7) 29.8 (6.1) 0.00 
Weight (Kg) 84.6 (20.4) 93.1 (20.3) -0.32  84.6 (20.4) 84.5 (19.7) 0.00 
SBP (mmHg) 132.6 (17.5) 135.0 (15.2) -0.11  132.6 (17.5) 132.7 (15.6) -0.01 
DBP (mmHg) 79.6 (10.5) 80.4 (9.3) -0.07  79.6 (10.5) 79.8 (9.2) -0.03 
TC (mmol/l) 5.1 (1.6) 4.8 (1.3) 0.16  5.1 (1.6) 5.1 (1.8) 0.00 
HDL (mmol/l) 1.2 (0.4) 1.1 (0.3) 0.12  1.2 (0.4) 1.2 (0.3) 0.00 
LDL (mmol/l) 2.8 (1.1) 2.7 (1.0) 0.14  2.8 (1.1) 2.8 (1.1) 0.04 
Triglyceride (mmol/L) 2.9 (5.8) 2.5 (3.2) 0.06  2.9 (5.8) 2.8 (6.0) 0.01 
Serum albumin (g/L) 42.0 (4.3) 42.8 (3.7) -0.17  42.0 (4.3) 42.0 (3.9) -0.01 
eGFR (mls/min/1.73m2) 74.1 (19.0) 75.8 (16.7) -0.08  74.1 (19.0) 74.4 (17.3) -0.02 
ACR (mg/mol) 4.8 (11.4) 3.6 (9.0) 0.11  4.8 (11.4) 4.2 (9.7) 0.06 
Diabetes duration (yrs) c 2.6 (4.6) 2.7 (3.1) -0.03  2.6 (4.6) 2.5 (3.8) 0.01 
Smoking status, No. (%)        
Non-smoker 619 (39) 1604 (44) -0.07  619 (39) 602 (38) 0.02 
Current smoker 435 (27) 669 (18) 0.16  435 (27) 458 (29) -0.03 
Ex-smoker 530 (33) 1381 (38) -0.07  530 (33) 524 (33) 0.01 
BMI Categories, No. (%)        
≤ 30kg/m2 918 (58) 1447 (40) 0.29  918 (58) 910 (57) 0.01 
30-34.9kg/m2 354 (22) 1167 (32) -0.18  354 (22) 368 (23) -0.02 
≥ 35kg/m2 312 (20) 1040 (28) -0.16  312 (20) 306 (19) 0.01 
Use of Medications, No. (%)        
Aspirin 220 (14) 734 (20) -0.14  220 (14) 242 (15) -0.04 
Antihypertensive 587 (37) 1873 (51) -0.22  587 (37) 581 (37) 0.01 
LLT 608 (38) 2136 (58) -0.31  608 (38) 585 (37) 0.03 
Comorbidities, No. (%) d        
Other CHD e 38 (2) 71 (2) 0.00  38 (2) 63 (4) -0.10* 
PAD 29 (2) 49 (1) 0.02  29 (2) 40 (3) -0.05 
Heart Failure 31 (2) 36 (1) 0.05  31 (2) 39 (2) -0.03 
Hypoglycaemia e 124 (8) 142 (4) 0.10  124 (8) 158 (10) -0.09* 
        
Abbreviations: MET (metformin); SU (sulphonylurea); DPP-4 (dipeptidyl peptidase-4 inhibitor); INS (insulin); BMI (body mass 
index); SBP (systolic blood pressure); DBP (diastolic blood pressure); HbA1c (haemoglobin A1c); HDL (high-density lipoprotein); 
LDL (low-density lipoprotein); TC (total cholesterol); GFR (glomerular filtration rate); LLT (lipid lowering therapy); PAD 
(peripheral arterial disease); CHD (coronary heart disease); ACR (urinary albumin creatinine ratio); SD (standard deviation) 
a Standardized differences are the absolute difference in means or percentage divided by the standard deviation of the treated group 
b Resulting standardized difference after 1:1 matching based on average treatment effect on treated (ATT) propensity score 
technique and robust variance estimation. See ESM Figure 5 for graphical illustration of balance 
c Diabetes duration is time from first diagnosis of diabetes to date of intensification with 3rd line drug (index date) 
d Comorbidities are defined in the Supplement (see Table 1 in the ESM) 
e In the matched cohort, only CHD and hypoglycaemia had statistically significant standardized difference at 0.10 level 
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Table 2: Numbers of Events, Rates and Adjusted Hazard Ratios 
 MET + SU + INS MET + SU + DPP-4 inhibitor 
Person-years 5,193 11,694 
Sample population   
Composite outcome (No. of events) a 231 171 
Median time to composite outcome (IQR) 2.1 (0.9-3.6) 2.4 (1.1-3.8) 
Unadjusted rate of outcome (95% CI) 44.5 (39.1-50.6) 14.6 (12.6-17.0) 
Adjusted hazard ratio (95% CI) 2.6 (1.9-3.4) 1.0 [Reference] 
   
Cardiovascular events (No. of events) b 95 94 
Unadjusted rate (95% CI) 18.4 (15.1-22.5) 8.1 (6.6-9.9) 
Adjusted hazard ratio (95% CI) 2.0 (1.5-2.8) 1.0 [Reference] 
   
All-cause deaths (No. of events) c 124 64 
Unadjusted rate (95% CI) 23.2 (19.5-27.7) 5.4 (4.2-6.9) 
Adjusted hazard ratio (95% CI) 3.7 (2.7-5.2) 1.0 [Reference] 
   
Cardiovascular deaths (No. of events) d 9 5 
Unadjusted rate (95% CI) 1.7 (0.9-3.3) 0.4 (0.2-1.0) 
Adjusted hazard ratio (95% CI) 2.6 (0.8-8.9) 1.0 [Reference] 
   
Subgroup population   
BMI <30kg/m2   
Composite outcome (No. of events) a 147 90 
Unadjusted rate (95% CI) 48.8 (41.2-57.4) 19.6 (16.0-24.1) 
Adjusted hazard ratio (95% CI) 3.08 (2.2-4.3) [Reference] 
   
BMI 30-34.9kg/m2   
Composite outcome (No. of events) a 54 44 
Unadjusted rate (95% CI) 46.4 (35.5-60.5) 11.8 (8.8-15.9) 
Adjusted hazard ratio (95% CI) 3.6 (2.3-5.6) 1.0 [Reference] 
   
BMI ≥ 35kg/m2   
Composite outcome (No. of events) a 30 37 
Unadjusted rate (95% CI) 29.6 (20.7-42.4) 11.2 (8.1-15.5) 
Adjusted hazard ratio (95% CI) 2.4 (1.4-4.0) 1.0 [Reference] 
   
Females   
Composite outcome (No. of events) a 105 67 
Unadjusted rate (95% CI) 39 (32.2-47.3) 14.4 (11.3-18.2) 
Adjusted hazard ratio (95% CI) 2.3 (1.7-3.3) 1.0 [Reference] 
   
Males   
Composite outcome (No. of events) a 126 104 
Unadjusted rate (95% CI) 50.4 (42.3-60) 14.8 (12.2-17.9) 
Adjusted hazard ratio (95% CI) 3.08 (2.32-4.09) 1.0 [Reference] 
   
Abbreviation: MET (metformin); SU (sulphonylurea); DPP-4 
(dipeptidylpeptidase-4 inhibitor); INS (insulin); BMI (body 
mass index) 
a Composite outcome include: non-fatal acute myocardial 
infarction (AMI), non-fatal stroke or all-cause death.  For full 
regression model of sample population, see ESM Table 2 
b Cardiovascular events relate to non-fatal AMI, non-fatal 
stroke or cardiovascular related deaths 
c All-cause deaths only include records with confirmed 
cause of death. Patients whose cause of death could not 
be verified were not included 
 
d Cardiovascular deaths refer to deaths from all 
cardiovascular causes 
 
Rates are calculated per 1000 person-years in all cases.  
 
